Seneca Biopharma Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Seneca Biopharma are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Low | High |
Very Weak
Over the last 90 days Seneca Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Seneca Biopharma is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
Fifty Two Week Low | 1.0700 | |
Target High Price | 26.00 | |
Fifty Two Week High | 13.8000 | |
Target Low Price | 26.00 |
Seneca |
Seneca Biopharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Seneca Biopharma on December 29, 2023 and sell it today you would earn a total of 100.00 from holding Seneca Biopharma or generate -100.0% return on investment over 90 days. Seneca Biopharma is generating negative expected returns assuming volatility of 0.0% on return distribution over 90 days investment horizon. In other words, 0% of stocks are less volatile than Seneca, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
Risk |
Seneca Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seneca Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Seneca Biopharma, and traders can use it to determine the average amount a Seneca Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
CUR |
Based on monthly moving average Seneca Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Seneca Biopharma by adding Seneca Biopharma to a well-diversified portfolio.
Seneca Biopharma Fundamentals Growth
Seneca Stock prices reflect investors' perceptions of the future prospects and financial health of Seneca Biopharma, and Seneca Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Seneca Stock performance.
Return On Equity | -0.0251 | |||
Return On Asset | -0.0109 | |||
Current Valuation | (3.42 M) | |||
Shares Outstanding | 2.64 M | |||
Price To Earning | (5.24) X | |||
Price To Book | 0.61 X | |||
Price To Sales | 260.50 X | |||
Revenue | 15.39 K | |||
EBITDA | (25.61 M) | |||
Cash Per Share | (1.82) X | |||
Debt To Equity | 7.80 % | |||
Cash Flow From Operations | (6.86 M) | |||
Earnings Per Share | (5.63) X | |||
Total Asset | 8.45 M | |||
Retained Earnings | (197.32 M) | |||
Current Asset | 6.69 M | |||
Things to note about Seneca Biopharma performance evaluation
Checking the ongoing alerts about Seneca Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Seneca Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Seneca Biopharma is not yet fully synchronised with the market data | |
Seneca Biopharma has some characteristics of a very speculative penny stock | |
Seneca Biopharma has a very high chance of going through financial distress in the upcoming years | |
The company reported the last year's revenue of 15.39 K. Reported Net Loss for the year was (6.63 M) with profit before taxes, overhead, and interest of 260 K. | |
Seneca Biopharma has about 7.3 M in cash with (6.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of -1.8233. | |
Roughly 14.0% of the company shares are held by company insiders |
- Analyzing Seneca Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Seneca Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Seneca Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Seneca Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Seneca Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Seneca Biopharma's stock. These opinions can provide insight into Seneca Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Seneca Stock
If you are still planning to invest in Seneca Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seneca Biopharma's history and understand the potential risks before investing.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |